Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409320 | SCV000486782 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2016-08-08 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001218630 | SCV001390520 | likely pathogenic | Spastic paraplegia | 2022-12-16 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 371248). This variant has not been reported in the literature in individuals affected with SACS-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Tyr4428*) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 152 amino acid(s) of the SACS protein. This variant disrupts the p.Asn4549 amino acid residue in SACS. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15156359, 21507954). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Revvity Omics, |
RCV000409320 | SCV002019115 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2021-04-16 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000409320 | SCV004210038 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2023-01-06 | criteria provided, single submitter | clinical testing |